Loading market dashboard
Phibro Animal Health Corporation
PAHCHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors need to pay close attention to PAHC stock based on the movements in the options market lately.
On May 28, 2026, Phibro Animal Health Corp (PAHC) shares fell 3.1% today, closing at $31.83. The stock has experienced significant volatility, trading between a
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Jaws & Paws Conference. Executive Vice President, Corporate Strategy & CEO Designate, Daniel Bendheim; Chief Operating Officer, Larry Miller; and Chief Financial Officer, Glenn David will address financial analysts and investors on Wednesday, May 27, 2026, at 9:45 AM ET at Lotte New York Palace in New York. The live audio presentation will be available on the.
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
Phibro Animal Health Corporation (PAHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Phibro (PAHC) could produce exceptional returns because of its solid growth attributes.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Review Phibro's (PAHC) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Phibro Animal Health Corporation (PAHC) Q3 2026 Earnings Call Transcript
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America Securities Health Care Conference. Executive Vice President, Corporate Strategy & CEO Designate Daniel Bendheim; Chief Operating Officer, Larry Miller and Chief Financial Officer, Glenn David will address financial analysts and investors on Wednesday, May 13, 2026, at 1:40 PM ET at Wynn and Encore in Las Vegas. The live audio presentation will be availab.
The headline numbers for Phibro (PAHC) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2026, and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025): Net sales of $383.5 million, an increase of $35.7 million, or 10% Net income of $24.0 million, an increase of $3.1 million, or 15% Dilute.
TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 24, 2026, to stockholders of record at the close of business on June 3, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livest.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the launch of its new Sustainable Solutions Platform (SSP), a companywide initiative designed to help animal protein, dairy and petfood producers address greenhouse gas emissions through practical, science-based solutions that integrate seamlessly into existing feed and production systems. As part of the SSP launch, Phibro is introducing Verratain™ Verified Sustainability Solutions, the Company's fir.
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Insulet (PODD). But which of these two stocks presents investors with the better value opportunity right now?
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 6, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 7, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-202.
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. NVDA, PAHC, FTI and BURL are some such stocks.
Zimmer Biomet tops Q1 EPS and revenue estimates with strong segment growth and margin expansion, yet shares slip 1.8% premarket after results.
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Brazil that have growth promotion indications. The Brazilian Ministry of Agriculture and Livestock (MAPA) published Ordinance No. 1617 on April 27, 2026, prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials classified as importan.
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
Phibro Animal Health Corporation (NASDAQ: PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $54.64, for a total value of $384,665.60. Following the sale, the chief executive officer directly owned 117,000 shares in
Phibro Animal Health Corporation (NASDAQ: PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $59.08, for a total transaction of $415,923.20. Following the completion of the transaction, the chief executive officer directly owned 31,080 shares
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?
Phibro Animal Health, Deluxe, Remitly Global and BrightSpring Health Services, Inc. (BTSG) represent four compelling small-cap stocks.
PAHC stock surges 152% in a year, fueled by strong animal health demand, Zoetis MFA integration and growing vaccine momentum.
Phibro Animal Health (NASDAQ: PAHC - Get Free Report) and TerrAscend (OTCMKTS:TSNDF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Earnings and Valuation This table compares Phibro Animal
How investors can find the best "Strong Buy" momentum stocks to add to their portfolios heading into April and throughout 2026.
Phibro Animal Health Corporation (NASDAQ: PAHC - Get Free Report) CEO Jack Bendheim sold 5,280 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $51.66, for a total value of $272,764.80. Following the completion of the sale, the chief executive officer owned 90,920 shares of
Shares of Phibro Animal Health Corporation (NASDAQ: PAHC - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, PAHC, ADSK and AMP are some such stocks.
EAT, PAHC and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 12th, 2026.
Citigroup Inc. lifted its position in Phibro Animal Health Corporation (NASDAQ: PAHC) by 112.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,941 shares of the company's stock after acquiring an additional 29,066 shares during the
